The study compared chlorambucil alone with chlorambucil in combination with plasma exchange in patients with polyneuropathy associated with mono-
pathy disability score improved by 2-1 points from baseline (21-0 to 18.9) in the chlorambucil group and by 1-8 points (20-4 to 18.6) in the chlorambucil + plasma exchange group (P = 0.70). The mean motor nerve conduction velocity decreased from 20-0 to 18-2 mis in the chlorambucil group and increased from 20 5 to 22-5 mis in the chlorambucil + plasma exchange group (P = 0.51). A slight improvement of the sensory component of the neuropathy disability score (from 10 5 to 8.3) was noted in both groups (P = 0*01). At the end of the study and according to self evaluation, 15 patients-eight from the chlorambucil group and seven from the chlorambucil + plasma exchange group-reported clinical improvement, whereas 15-eight from the chlorambucil group and seven from the chlorambucil + plasma exchange group-reported clinical worsening. Neuropathy remained stable in the others.
Thus plasma exchange seemed to confer no additional benefit in the treatment of polyneuropathy associated with monoclonal IgM.
(_ Neurol Neurosurg Psychiatry 1995;59:243-247) Keywords: polyneuropathy; antimyelin; gammopathy; plasma exchange Peripheral neuropathy may be associated with a serum monoclonal IgM in the presence or absence of an overt lymphoid proliferative disease such as Waldenstrom's macroglobulinaemia.1-3 A causal link between the monoclonal IgM and the development of neuropathy is suggested by (a) the specificity of most of these IgMs for the myelin associated glycoprotein (MAG),4 5 nerve glycolipids,"8 or gangliosides9; (b) the detection of IgM and complement deposits by immunofluorescence, on the myelin sheaths of nerve biopsies from patients2 10 11; (c) the induction, in animal models, of the neuropathological process through the transfer of the anti-MAG IgM"2 13 or by the subperineural injection of the IgM in peripheral nerves.14 Because IgM associated neuropathy usually has a progressive course and can be responsible for severe disabling sensory and motor symptoms, effective treatment is important. The rationale for using plasma exchange is that the monoclonal IgM may be directly involved in the demyelination and removal of these pathogenic antibodies may prevent progression of the neuropathy or even lead to improvement. The rationale for using chlorambucil is that even in the absence of a detectable lymphoid proliferation, the monoclonal IgM is associated with an underlying IgM producing B cell clone; chlorambucil is effective in chronic B cell neoplasias such as chronic lymphocytic leukaemia and Waldenstr6m's macroglobulinaemia and could therefore be effective on the anti-MAG secreting B cells. Plasma exchange and chlorambucil have been used with some improvement in uncontrolled studies enrolling few patients.' [15] [16] [17] As evaluation of these therapeutic strategies require long term treatment and as the idea of a placebo arm was considered unethical because of the progressive disability associated with such disease, we points of the initial CNDS in the group treated with chlorambucil and plasma exchange and postulating that the disease would be stable in the group receiving chlorambucil alone, we decided to enroll 44 consecutive patients in the study (a = 0 05, ,B = 0-05).
TREATMENT
The patients were assigned by randomisation to receive chlorambucil alone (O-1 mg/kg/day, orally) for 12 months, or in association with a four month period of plasma exchange. 1 8 points in the chlorambucil + plasma exchange group. The difference between the two groups was not statistically significant (P = 070). The slight improvement in both groups was related to an improvement of the sensory component of the CNDS: 2-4 points in the chlorambucil group and 1-5 points in the chlorambucil + plasma exchange group. In the whole population of patients this improvement of the CNDS(S) score from 10-5 to 8-3 was statistically signifi- 
CNDS(M):
At entry 9-6 (5 7) 11-2 (4-8) Electrophysiological data were available in 39 patients. Nerve conduction studies showed that with chlorambucil alone, the mean value of MNCV (peroneal nerve) worsened by 1-8 m/s and that the mean value of DL improved by 3-3 ms. In the chlorambucil + plasma exchange group the mean value of MNCV improved by 2 m/s and the mean value of DL by 3 ms. The differences between the two groups were not significant. Sensory nerve conduction velocities in the sural nerve were undetectable in 32 of the 39 patients at entry, and in 21 of the 32 patients evaluated at month 12.
Twenty nine patients remained stable or worsened, and 15 improved after treatment. We looked for baseline covariates that could be predictive for the response, and failed to find any predictive value for age, sex, bone marrow lymphoid infiltration, serum IgM concentration, antimyelin activity, or initial CNDS; There was a trend for shorter duration of the neuropathy in the responders (26-3 (23) months) than in the non-responders (42.6 (40) months), but it did not reach significance (P = 0-15). The response was not associated with a significant decrease in the serum IgM concentration in the 29 patients in whom it could be evaluated.
Long term follow up (47 to 83 months) was available for 14 of the 15 patients who had responded to treatment. At the end of the study two of them stopped taking chlorambucil; one patient had achieved a complete response and remained symptom free after 80 months while the serum monoclonal IgM was still detectable (2 to 3 g/l); the other relapsed at month 24 but improved again when chlorambucil was reintroduced. Of the 12 patients who were maintained on chlorambucil, six remained stable on treatment, four stopped In the present study, the association of plasma exchange with chlorambucil offered no additional benefit as measured by the neuropathy disability score (P = 070), its motor component (P = 0-12), its sensory component (P = 070), or the motor nerve conduction velocity (P = 0-5 1). Interestingly, after four months of treatment, when the patients of one group had completed their plasma exchange that is, at the time at which we were most likely to detect a difference between the two groups-we failed to show any usefulness of plasma exchange (table 4) .
For both groups together, treatment was associated with a slight improvement of the CNDS, from 21-0 to 18-8 (P = 005) as a sole result of the improvement its sensory component, from 10-5 to 8-3 (P = 0 01). There was no significant modification of the nerve conduction velocity neither of the distal latency.
Of note, after 12 
